Amicus Therapeutics outlines $86M IPO
Amicus Therapeutics has filed for an IPO designed to raise up to $86.25 million. Amicus has been developing therapies for chronic genetic disorders. Its lead drug is Amigal, in Phase II as a therapy for Fabry's disease. Most of the money raised in the IPO is earmarked for clinical development work.
- here's the release on the offering
Comments